Manhattan Scientifics, Inc. (MHTX)

[Hncher]

Of course Proulx is hoping to improve the tech, that's nothing new and I am hoping he pulls it off, that's what people do when they invest in early tech companies.

Imagion Biosystems identifies key operational objectives

http://www.asx.com.au/asxpdf/20170712/pdf/43klfjglymg9gx.pdf

MELBOURNE — July 12, 2017 — Imagion Biosystems Limited (Imagion, ASX:IBX), is pleased to provide shareholders and interested parties an outline of its operational objectives as it moves toward first-in-human
testing after the completion of its $12 million IPO and subsequent ASX listing.

The consensus within the medical community is that more lives could be saved if cancer could be detected earlier, but as too many of us know, cancer continues to be one of the leading causes of mortality. Imaging
methods such as MRI, PET and ultrasound, are neither sensitive enough nor specific enough to catch cancer early and effect treatment decisions.

It is clear that the sooner patients and physicians are aware of cancer, the more choices for treatment and positive outcomes there will be. Imagion’s MagSense™ magnetic relaxometry technology holds great promise to positively change the way cancer is diagnosed.

The path to first-in-human testing
The IPO funding has now provided Imagion with the working capital needed to work through the scientific and regulatory steps on the path to commercialization. As outlined in the offering Prospectus, the next major business milestone will be achieving first-in-human testing, which is anticipated to occur approximately 18 months from now. In the interim we expect to measure our progress against four key business objectives:
• Establish the sites for our initial breast cancer study.
• Complete the safety testing of our nanoparticles for human use.
• Initiate development and manufacturing of our MagSense instrument.
• Establish GMP supply of our nanoparticles for the breast cancer test.

Imagion will also continue to pursue its important scientific
collaborations with MD Anderson, and others, to progress each of the cancer diagnostic programs and advance the technology. In saying this, the primary focus will remain on the drive to first clinical studies and the route to early commercialization of the technology.